Navigation Links
ScreenCancer Adds InSure(R) FIT(TM) Colorectal Cancer Screening Test to European Cancer Screening Program
Date:2/26/2009

OSLO, Norway, February 26 /PRNewswire/ -- ScreenCancer AS, a Norwegian company offering cancer screening management services to employers, insurance companies and individuals, today announced that it has added the InSure(R) FIT(TM) take-at-home colorectal cancer screening test to its European Cancer Screening Program. The company's two-year distribution agreement with Enterix Inc., a subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), the world leader in diagnostic testing, information and services, grants ScreenCancer limited exclusive rights to offer InSure FIT in 24 countries of the European Economic Union, including France, Germany and the U.K.

Colon cancer is the second most common form of cancer in Europe. In 2004, 376,400 people contracted the illness while 203,700 colon cancer patients died. Despite considerable progress in treatment, the mortality rate in Europe has remained high and it has been concluded that it can only be reduced through an intensive campaign of prevention and screening.[1][2] Medical experts recommend annual screening for all patients over age 50 at average risk, younger for those at higher risk.

"We are pleased to provide annual colorectal cancer screening with InSure FIT to our customers," said Christian Horn, CEO of ScreenCancer. "Colorectal cancer is often treatable and even preventable when caught early, which is why annual screening with the InSure FIT test is so important. The test has been shown to be highly effective in helping to detect colorectal cancers earlier, and, we believe, is the easiest test for patients to use, making it an important component of our program designed to increase screening rates for the major cancers."

InSure FIT features a unique long-handled blue brush to collect two water-based samples - rather than the solid samples required by other FITs (fecal immunochemical tests) or FOBTs (fecal occult blood tests) - and does not require any change in patient diet or medication. In one study, patients were 66% more compliant in completing their InSure FIT test compared to a leading guaiac-based FOBT test.[3] Information about the InSure FIT test is available at http://www.doyouhavetheguts.com.

A recent interim study conducted at the Flinders Centre for Innovation in Cancer (Australia) and presented at the annual Digestive Disease Week Conference in May 2008 found that, in patients with a family or personal history of colorectal cancer or adenoma who completed an annual FIT, detection of cancerous lesions occurred an average of 26.5 months earlier than would have occurred during the three- or five-year study-required colonoscopy alone. Detection of precancerous lesions in this group occurred 18.4 months earlier.[4]

"Quest Diagnostics is committed to expanding the number of people getting screened annually for colorectal cancer, and ScreenCancer is a valued partner in that endeavor," remarked Paul Rust, Quest Diagnostics' Vice President, Point of Care Testing. "ScreenCancer's introduction of an innovative, comprehensive cancer screening program in the European commercial market, combined with tests such as the InSure FIT colorectal cancer screening test, promise to help improve cancer screening rates, and as a result, through early detection, help save lives."

About ScreenCancer, AS

ScreenCancer AS provides cancer screening management services to self-insured employers and individuals. ScreenCancer offers a private alternative where little or no public cancer screening program exists. With a panel of the leading screening tests for several major cancers, and clinical follow-up by experts in the field, ScreenCancer provides a method for employers and individuals to help reduce the risk and negative effects of cancer. For more information, please visit the company's web site at http://www.screencancer.com.

    ---------------------------------

    [1] Classen, Lambert, "Colorectal Cancer Screening in Europe, a Survey of
        the International Digestive Disease Alliance between November 2004
        and March, 2007"

    [2] Boyle, P., Ferlay, J., "Cancer incidence and mortality in Europe. Ann
        Onco 2005; 16: 481-488

    [3] Cole SR, Young GP, Esterman A, Cadd A, Morcom J. A randomised trial
        of the impact of new faecal haemoglobin test technologies on
        population participation in screening for colorectal cancer. J Med
        Screen 2003;10:117-122.

    [4] The study abstract is published in the April 2008 supplement of
        Gastroenterology


    For more information contact:
    Christian Horn, CEO,
    Phone: +47-90163153,
    Christian.horn@screencancer.com .


'/>"/>
SOURCE ScreenCancer AS
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cancer Advances Acquires the Intellectual Property for a Suite of Products that Enhance the Immune System in Treatment of Gastric, Pancreatic, and Colorectal Cancers
2. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
3. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
4. New Colorectal Module From Simbionix Advances Laparoscopic Cancer Treatment
5. GeneNews appoints Canadian Colorectal Cancer Advisory Board
6. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
7. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
8. NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER
9. GeneNews launches worlds first blood test for colorectal cancer screening
10. Genmab Initiates Zalutumumab Combination Study in Colorectal Cancer
11. Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... ... ... Any expert in stem cell research or stem cell medicine knows well the ... Despite their essential roles in human health and regenerative medicine, adult tissue stem ... this purpose also tag other, more abundant, non-stem tissue cells ( See 2017 Cell ...
(Date:8/15/2017)... (PRWEB) , ... August 15, 2017 , ... The ... time on Immuno-Oncology 360° (IO360°) programming through a series of upcoming panels and events. ... February 7-9, 2018, at The Roosevelt Hotel in New York City. , “With our ...
(Date:8/15/2017)... ... August 15, 2017 , ... JULABO USA introduces ... the new website makes it easy to navigate through the site whether you’re ... find detailed product information, educational industry content and visit the company’s social media ...
(Date:8/14/2017)... ... August 14, 2017 , ... Opal ... using USB or PCI Express, announced the release of SYZYGY™, a new open ... satisfy the need for a compact, low cost, low pin-count, high-performance connectivity solution ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/30/2017)... HONG KONG , March 30, 2017 ... developed a system for three-dimensional (3D) fingerprint identification by adopting ground ... technology into a new realm of speed and accuracy for use ... applications at an affordable cost. ... ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
Breaking Biology News(10 mins):